Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab-Reference-Cited by-同舟云学术

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

Published:2017-08-01 Issue:8 Volume:74 Page:961
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Baker David¹,Herrod Samuel S.¹,Alvarez-Gonzalez Cesar¹,Giovannoni Gavin²,Schmierer Klaus²

Affiliation:

1. Centre for Neuroscience and Trauma, Blizard Institute, Queen Mary University of London, England

2. Centre for Neuroscience and Trauma, Blizard Institute, Queen Mary University of London, England2Emergency Care and Acute Medicine, Clinical Academic Group Neuroscience, Barts Health NHS (National Health Service) Trust, The Royal London Hospital, London, England

Publisher

American Medical Association (AMA)

Subject

Clinical Neurology

Cited by 202 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: tumefactive demyelinating lesions after the second cycle of alemtuzumab in multiple sclerosis; immune cell profile and biomarkers;Frontiers in Immunology;2024-07-03

2. Distinct disease-modifying therapies are associated with different blood immune cell profiles in people with relapsing-remitting multiple sclerosis;International Immunopharmacology;2024-04

3. Alemtuzumab-induced thyroid eye disease successfully treated with a single low-dose of rituximab;European Thyroid Journal;2024-03

4. Peripheral memory B cells in multiple sclerosis vs. double negative B cells in neuromyelitis optica spectrum disorder: disease driving B cell subsets during CNS inflammation;Frontiers in Cellular Neuroscience;2024-02-07

5. Alemtuzumab‐induced immune‐mediated thrombotic thrombocytopenic purpura: A newly described drug‐related autoimmune disease;British Journal of Haematology;2023-12-19